Loading company…
Platbio develops drugs using a research platform that identifies therapeutic targets, particularly in cancer.
Founded in 2018 and based in Suwon, Platbio develops drugs using PRIINT™, a platform that combines genomics, proteomics and animal models to identify therapeutic targets, particularly in oncology. It also provides drug efficacy evaluation, treatment development, repositioning, CRO and consulting services. In October 2021, the company raised KRW 4.8 billion in Series B funding from Kolon Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in